Why the study?
HCN channels are promising targets for cardioprotective agents, warranting review of compounds with cardioprotective properties among biaromatic structures.
HCN channel blockers with biaromatic structures are highlighted as promising cardioprotective agents due to their selective bradycardic properties.
HCN4 blockade merits targeted investigation for cardioprotection; leaves open clinical validation in randomized trials.
Hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, primarily their HCN4 subtype, are one of the promising targets for the development of cardioprotective agents. HCN channel blockers have a selective bradycardic effect, preserving myocardial contractility and diastolic function and not affecting the electrophysiological parameters of the heart. This review continues a series of reviews on the analysis of compounds with cardioprotective properties in a number of biaromatic structures, which include a wide range of HCN channel blockers.
No takes yet. Share an insight, caveat, or question.
Г. В. Мокров (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: